Xray Volume Imaging (Cone Beam CT) - Prostate Cancer

A Clinical Study of X-ray Volume Imaging to Evaluate the Daily Set-up Accuracy of Conformal Prostate Radiotherapy

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00188799

Enrollment

Registered

2005-09-16

Start date

2003-11-30

Completion date

2004-11-30

Last updated

2015-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Neoplasms

Brief summary

Conformal dose escalated radiotherapy was adopted as the standard treatment technique at PMH for intermediate risk patients with localised disease in 1997. This technique provides a much smaller margin of error for treatment set-up and delivery than with conventional techniques. One way to ensure the accuracy of treatment delivery is to image the prostate position daily, prior to therapy, to allow for appropriate set-up corrections. To do so, imaging markers are implanted into the prostate under guided ultrasound (a standard procedure at PMH). However, there are disadvantages in using imaging markers which include added time to the treatment planning process, and an invasive procedure with a potential for discomfort, bleeding and infection. This study will investigate and compare X-ray volume imaging to the gold standard imaging markers.

Interventions

PROCEDUREdaily Xray volume imaging for planning radiotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of adenocarcinoma of the prostate * Patient undergoing escalated dose conformal external beam radiotherapy. * Patient has low or intermediate risk prognostic factors: all of PSA \<21, Gleason score \<8, clinical T category \<T3, clinical N category 0 or X, M category 0 or X. * Informed consent

Exclusion criteria

* No diagnosis of adenocarcinoma of the prostate * Patient not undergoing escalated dose conformal radiotherapy * Patient does not have low or intermediate risk prognostic factors

Design outcomes

Primary

Measure	Time frame
To evaluate he feasibility of daily X-ray volume imaging during conformal radiotherapy.	—

Secondary

Measure	Time frame
To provide preliminary data concerning the relative utility of daily X-ray volume image matching compared to fiducial marker image matching.	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026